title: [Pathogenesis and novel therapy for EBV-related B-cell lymphoma].
abstract: Epstein-Barr virus (EBV), a type of γ-herpes virus, is known to be a tumor virus. About 90% of adults were found to be persistently infected with EBV and this infection is responsible for Burkitt lymphoma (BL), extranodal NK/T cell lymphoma, Hodgkin lymphoma (HL), acquired Immune deficiency syndrome (AIDS)-associated lymphoma, and a portion of diffuse large B cell lymphomas (DLBCL). EBV-positive DLBCL in the elderly, a disease recognized in Japan, is described in the WHO classification as a new category of DLBCLs. Clinical studies of DLBCLs have since accumulated. We herein describe our clinicopathological study of EBV-positive DLBCL in the elderly in the rituximab era, and review EBV-positive B cell lymphoma cases. A potentially promising novel therapy for EBV-positive B cell lymphoma, anti-PD-1 antibody, is then introduced. Finally, we briefly discuss our unpublished study of EBV-positive B cell lymphoma and its microenvironment.
authors: Division of Hematology and Oncology, Department of Internal Medicine, Tokai University School of Medicine.
authors: Ai
authors: A
authors: Sato
authors: Natsuko
authors: N
authors: Yamakawa
authors: Ai
authors: A
authors: Kotani
mesh_terms: D020031:Epstein-Barr Virus Infections / Q000150:complications*; D055354:Exosomes; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000276:immunology / Q000628:therapy / Q000821:virology; D035683:MicroRNAs / Q000235:genetics; D011379:Prognosis
chemical_list: D035683:MicroRNAs